Press monitoring
Sanofi Pasteur Provides Key Support to the Human Vaccines Project
14.1.2016 | Press monitoring
Lyon, France - January 14, 2015 - Sanofi Pasteur , the vaccines division of Sanofi , has signed an agreement with the Human Vaccines Project Inc. to partially fund the non-profit, public-private partnership convening leading academic researchers and industrial partners to solve the primary problems impeding vaccine/immunotherapy development by...
Artificial pancreas system aimed at type 1 diabetes mellitus
13.1.2016 | Press monitoring
Researchers will soon undertake one of the largest-ever long-term clinical trials of a system designed to help regulate blood sugar levels of individuals with type 1 diabetes mellitus. If the scientists’ so-called artificial pancreas system performs in patients as they hope, it could lead to commercial trials and eventual regulatory approval in...
Sanofi and Innate Pharma Collaborate on New Bispecific NK Cell Engagers in Immuno-Oncology
11.1.2016 | Press monitoring
Paris and Marseille, France - January 11, 2016 - Sanofi and Innate Pharma today announced that they have entered into a research collaboration and licensing agreement to apply Innate Pharma's new proprietary technology to the development of innovative bispecific antibody formats engaging natural killer (NK) cells to kill tumor cells through the...
Sanofi and Warp Drive Bio to Collaborate on the Development of Novel Oncology Therapies and Antibiotics Based on Proprietary Platforms
11.1.2016 | Press monitoring
Paris, France - January 11, 2016 - Sanofi and Warp Drive Bio , a privately held biotechnology company using the molecules and mechanisms of nature to discover and develop transformative medicines, today announced that they have extended and reshaped their existing collaboration utilizing Warp Drive's proprietary SMART(TM) (Small Molecule Assisted...
Medtronic IN.PACT Admiral DEB Receives CE Mark for Treatment of AV Access In Patients with End-Stage Renal Disease
11.1.2016 | Press monitoring
DUBLIN - January 11, 2016 - Medtronic plc (NYSE:MDT), a global leader in medical technology, services and solutions, today announced that the IN.PACT ® Admiral ® drug eluting balloon (DEB) (also known as the IN.PACT Admiral drug-coated balloon (DCB) in non-European markets) has received CE (Conformité Européene) Mark for arteriovenous (AV) access...
Gene editing technique improves vision in rats with inherited blindness
11.1.2016 | Press monitoring
A new technique that has the potential to treat inherited diseases by removing genetic defects has been shown for the first time to hinder retinal degeneration in rats with a type of inherited blindness, according to a Cedars-Sinai study. A research team at the Cedars-Sinai Board of Governors Regenerative Medicine Institute focused on inherited...
Could bug-busting viruses control food poisoning?
8.1.2016 | Press monitoring
Viruses that can seek and destroy food poisoning bugs in the gut are being investigated by researchers at The University of Nottingham, thanks to a new grant. The work, which has been funded with a $100,000 USD grant by the Bill & Melinda Gates Foundation, could offer the potential for treating and preventing intestinal illnesses in children in...
Biocartis and Merck to Collaborate on New Liquid Biopsy Technology for RAS Biomarker Testing
7.1.2016 | Press monitoring
Mechelen, Belgium, January 07, 2016 - Biocartis, an innovative molecular diagnostics company, today announced that Biocartis has signed a collaboration agreement with Merck KGaA (Merck) for the development and commercialization of a new liquid biopsy RAS biomarker test for patients with metastatic colorectal cancer (mCRC). The test will be...
FIT Biotech focusing on gene therapy
7.1.2016 | Press monitoring
The Board of Directors of the Finnish biotechnology company FIT Biotech Oy (NASDAQ: FITBIO) has reviewed the company's on-going development projects and made a strategic decision to develop applications for gene therapy besides vaccine development. The decision is based on the good results of the functionality of the GTU® technology already...
Novo Nordisk files for regulatory approval of long-acting factor IX in the EU for the treatment of haemophilia B
7.1.2016 | Press monitoring
Bagsvaerd, Denmark, 7 January 2016 - Novo Nordisk today announced the submission to the European Medicines Agency of the Marketing Authorisation Application for the approval of long-acting factor IX, nonacog beta pegol. Nonacog beta pegol is a glycopegylated recombinant factor IX with a significantly improved pharmacokinetic (PK) profile,...
